Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.857
AS - Asia 20.649
EU - Europa 13.351
SA - Sud America 2.908
AF - Africa 468
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 22
Totale 60.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.984
SG - Singapore 6.955
HK - Hong Kong 3.889
VN - Vietnam 3.853
IT - Italia 3.477
RU - Federazione Russa 3.017
CA - Canada 2.651
CN - Cina 2.638
BR - Brasile 2.157
IE - Irlanda 1.776
DE - Germania 1.464
SE - Svezia 1.246
BD - Bangladesh 799
IN - India 675
FR - Francia 598
GB - Regno Unito 450
AR - Argentina 274
KR - Corea 256
UA - Ucraina 254
IQ - Iraq 235
FI - Finlandia 225
ID - Indonesia 209
TR - Turchia 180
NL - Olanda 178
ZA - Sudafrica 148
PK - Pakistan 146
AT - Austria 128
MX - Messico 119
JP - Giappone 117
ES - Italia 116
PH - Filippine 107
SA - Arabia Saudita 107
EC - Ecuador 105
CO - Colombia 98
PL - Polonia 94
VE - Venezuela 91
MY - Malesia 77
UZ - Uzbekistan 58
DK - Danimarca 55
EG - Egitto 53
CL - Cile 50
PY - Paraguay 49
BE - Belgio 46
KE - Kenya 45
MA - Marocco 43
JO - Giordania 38
TN - Tunisia 37
PE - Perù 36
NP - Nepal 35
DZ - Algeria 33
AE - Emirati Arabi Uniti 32
CZ - Repubblica Ceca 31
ET - Etiopia 30
AZ - Azerbaigian 26
AU - Australia 25
CH - Svizzera 25
JM - Giamaica 23
RO - Romania 23
BO - Bolivia 21
LB - Libano 21
LT - Lituania 21
TH - Thailandia 21
AL - Albania 20
IL - Israele 20
PT - Portogallo 20
TW - Taiwan 20
UY - Uruguay 20
CR - Costa Rica 19
PS - Palestinian Territory 18
SN - Senegal 18
OM - Oman 17
IR - Iran 15
PA - Panama 13
AO - Angola 12
BG - Bulgaria 12
EU - Europa 12
KG - Kirghizistan 12
LY - Libia 11
DO - Repubblica Dominicana 10
GR - Grecia 10
KZ - Kazakistan 10
HN - Honduras 9
RS - Serbia 9
BH - Bahrain 8
NO - Norvegia 8
SK - Slovacchia (Repubblica Slovacca) 8
BY - Bielorussia 7
GA - Gabon 7
GT - Guatemala 7
HU - Ungheria 7
KW - Kuwait 7
MD - Moldavia 6
MM - Myanmar 6
MN - Mongolia 6
NG - Nigeria 6
NI - Nicaragua 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
CI - Costa d'Avorio 5
EE - Estonia 5
Totale 60.188
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.828
Singapore 3.713
Toronto 2.413
Ashburn 1.990
San Jose 1.739
Dublin 1.719
Ann Arbor 1.271
Ho Chi Minh City 1.217
Frankfurt am Main 1.034
New York 1.009
Hanoi 1.001
Milan 917
Princeton 888
Santa Clara 682
Chicago 680
Fairfield 672
Chandler 662
The Dalles 653
Dallas 585
Los Angeles 569
Houston 470
Woodbridge 464
Lauterbourg 422
Moscow 363
Beijing 340
Rome 334
Lawrence 329
Altamura 321
Wilmington 317
Hefei 285
Buffalo 264
Seattle 259
Cambridge 250
Seoul 239
São Paulo 200
Shanghai 186
Council Bluffs 176
Jacksonville 174
San Diego 163
Pune 162
Dearborn 143
Da Nang 136
Helsinki 133
Jakarta 133
Haiphong 124
London 111
Orem 101
Baghdad 100
Boardman 92
Tokyo 92
Andover 89
Salt Lake City 87
Rio de Janeiro 85
Nuremberg 84
Hải Dương 74
Washington 73
Guangzhou 71
Johannesburg 70
Quận Bình Thạnh 69
Warsaw 69
Chennai 67
Vienna 66
Brooklyn 65
Montreal 65
Munich 65
Nanjing 62
Atlanta 61
Turin 61
Thái Nguyên 57
Biên Hòa 54
Dhaka 53
Naples 53
Phoenix 52
Boston 51
Ha Long 50
Hangzhou 50
Columbus 49
Denver 48
Figino 48
Kuala Lumpur 47
Tashkent 47
Vũng Tàu 46
Mumbai 44
Ninh Bình 44
Stockholm 44
Lahore 42
Amsterdam 41
Brasília 40
Can Tho 40
San Francisco 40
Florence 39
Fremont 39
Belo Horizonte 38
Bergamo 38
Tampa 38
Istanbul 37
Lappeenranta 37
Quito 37
Riyadh 37
Bắc Ninh 36
Totale 36.824
Salva come PNG Salva come JPEG
Nome #
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma 1.325
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group 508
Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy 479
Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients 466
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 459
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 388
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 364
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 360
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 345
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 342
Health related quality of life in chronic liver diseases 340
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 329
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 323
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 318
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 316
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 315
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 310
The impact of liver disease on the health-related quality of life 306
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 305
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 304
High rates of 30-day mortality in patients with cirrhosis and COVID-19 303
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 296
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 292
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 291
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 289
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 287
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 286
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 283
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 282
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 275
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 273
Health Related Quality of Life in the Major Liver Conditions 270
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 268
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 264
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 260
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 256
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 254
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 253
Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients 251
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group (Hepatology International, (2024), 18, 5, (1416-1430), 10.1007/s12072-024-10703-4) 250
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 250
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 246
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 244
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 243
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 242
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 242
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 240
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 239
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 235
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 234
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 234
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 231
Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes 229
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 229
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 228
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 228
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 228
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 223
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 222
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 222
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 222
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 221
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 217
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 215
Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center 214
Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence 211
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 210
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 209
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue 208
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 206
Non-anatomical revascularization of the portal vein in children with non-cirrhotic extrahepatic portal vein obstruction 205
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 204
Antibiotic Stewardship Based on Colonization with Multi-Drug-Resistant Bacteria in Liver Transplantation: A Narrative Review 204
Bergamo and Covid-19: How the Dark Can Turn to Light 204
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 203
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 203
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 202
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 201
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 199
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study 195
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 194
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool 193
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 192
Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion 192
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 187
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 184
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 183
Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 182
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 182
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study 181
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 181
Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study 179
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 179
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 178
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 178
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 178
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 177
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 176
Bulevirtide improves liver function in candidates for liver transplant with advanced HDV cirrhosis and severe portal hypertension 174
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 173
Totale 26.170
Salva come PNG Salva come JPEG
Categoria #
all - tutte 254.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 254.901
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/202514.328 822 1.742 601 606 1.226 389 614 462 2.010 1.826 966 3.064
2025/202629.097 2.866 1.925 1.987 2.256 2.707 1.476 3.916 1.460 2.382 2.405 3.361 2.356
2026/2027239 239 0 0 0 0 0 0 0 0 0 0 0
Totale 61.939